Skip to main content

Cambia FDA Approval History

FDA Approved: Yes (First approved June 17, 2009)
Brand name: Cambia
Generic name: diclofenac potassium
Dosage form: for Oral Solution
Previous Name: PRO-513
Company: Kowa Pharmaceuticals America, Inc.
Treatment for: Migraine

Cambia (diclofenac potassium) is a non-steroidal anti-inflammatory drug combined with potassium bicarbonate for the treatment of acute migraine with or without aura in adults.

Development timeline for Cambia

DateArticle
Jun 23, 2009Approval FDA Approves Cambia for Migraine
Dec 12, 2007ProEthic Pharmaceuticals Announces Acceptance of PRO-513 New Drug Application for Migraine

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.